Disease Education Resources
Please select your disease state of interest to explore medical education resources.
A short educational series of videos & slides about Ki-67 as a prognostic factor for recurrence in patients with HR+/HER2- EBC
~20% of patients with HR+/HER2- EBC may progress to metastatic disease, commonly within a few years after primary treatment. This slide deck provides details on the clinical & pathological factors that may affect the risk of recurrence in people with EBC.
This slide deck provides information on covalent and reversible (non-covalent) BTK inhibition in the treatment of B-cell malignancies, and a growing unmet need of resistance to covalent BTK inhibition.